Conversion to Resection in Patients Receiving Systemic Chemotherapy for Unresectable and/or Metastatic Colorectal Cancer—Predictive Factors and Prognosis
- 1 March 2018
- journal article
- research article
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 17 (1) , e91-e97
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Colorectal Cancer Survival Gains and Novel Treatment RegimensJAMA Oncology, 2015
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancerInternational Journal of Clinical Oncology, 2015
- S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trialThe Lancet Oncology, 2012
- Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysisInternational Journal of Colorectal Disease, 2012
- A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resectionAnnals of Oncology, 2011
- Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trialBritish Journal of Cancer, 2009
- Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panelAnnals of Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Capecitabine (Xeloda®) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumorsAnnals of Oncology, 2002
- Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trialThe Lancet, 2000